secwatch.observer — SEC 8-K summary
======================================

Issuer:     ASSEMBLY BIOSCIENCES, INC. (ASMB)
CIK:        0001426800
Form:       8-K
Filed at:   2026-05-22T11:15:16+00:00
Accession:  0001193125-26-235469
Event type: other_material
Sentiment:  positive
Materiality: 0.65
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Assembly Biosciences expands ABI-6250 into PBC and PSC; Phase 2 basket study planned Q1 2027
--------------------------------------------------------------------------------

- ABI-6250, oral NTCP inhibitor, to be studied in PBC and PSC basket Phase 2 starting Q1 2027.
- Phase 1a completed; data show dose-dependent bile acid elevations confirming target engagement.
- Chronic tox studies support longer-term dosing; Phase 2 in HDV remains on track for Q4 2026.
- Pre-IND FDA meeting constructive; company views feedback as helpful for advancement.
- PSC has no approved therapies; PBC has significant unmet need despite existing treatments.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1426800/000119312526235469/0001193125-26-235469-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1426800/000119312526235469/asmb-20260522.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-235469

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer